Dasotraline: Additional Ph II/III SEP360-202 data

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary reported additional data from the double-blind, U.S. Phase II/III SEP360-202 trial in 342 ADHD patients ages 6-12 showing that once-daily ...